Ataraxis AI develops clinical AI tools to predict disease outcomes and treatment responses, focusing on breast cancer with its Ataraxis™ Breast platform.
Ataraxis AI specializes in AI precision medicine, developing advanced multi-modal tools to assist physicians in improving treatment selection and patient outcomes. Their core technology integrates information from various digital data modalities using pioneering artificial intelligence methods. These systems discover novel clinical, morphological, and molecular features of patients and their disease, capturing cancer heterogeneity beyond single data types. The company's proprietary technology analyzes multi-modal patient data to assess disease aggressiveness, predict cancer recurrence or death risk, and evaluate the benefits of different treatment options. Ataraxis™ Breast is an AI-native platform offering clinically validated prognostic and predictive tools specifically for breast cancer. All Ataraxis tests are built on AI foundation models, such as Falcon, trained on hundreds of millions of pan-cancer pathology slide images to extract information about tumor morphology that correlates with patient outcomes and treatment response. Ataraxis AI aims to personalize treatment by predicting patient outcomes and treatment responses through novel AI methods applied to multi-modal data. Their process offers same-day turnaround times for analysis results and does not exhaust physical tissue, unlike traditional molecular genomic tests.
Platforms: Web
View full Ataraxis AI profile on Tools-Radar | Browse Healthcare tools | Alternatives to Ataraxis AI
Tools-Radar is a free directory of 10,000+ AI tools — discover, compare, and choose the right AI software for your needs. Visit tools-radar.com